相关实验视频

Updated: May 13, 2026

Synthesis and Characterization of mRNA-Loaded Poly(Beta Aminoesters) Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded Poly(Beta Aminoesters) Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

COVID-19 mRNA XBB.1.5的成本效益分析2023年秋季荷兰的疫苗接种

Florian Zeevat1,2, Simon van der Pol3,4, Tjalke Westra5

  • 1Health-Ecore, Utrechtseweg 60, 3704 HE, Zeist, The Netherlands. florianzeevat@health-ecore.com.

Advances in therapy
|February 10, 2025
PubMed
概括

对于荷兰的高风险人群来说,mRNA-1273 COVID-19 疫苗比 BNT162b2 具有显著的健康和经济益处. 如果价格具有竞争力,并确保国家免疫计划的成本效益,建议采用该方案.

关键词:
在 COVID-19 疫情中,成本效益分析的成本效益分析经济评估 经济评价疫苗接种 疫苗接种

更多相关视频

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

Pseudotyped Viruses As a Molecular Tool to Monitor Humoral Immune Responses Against SARS-CoV-2 Via Neutralization Assay05:49

Pseudotyped Viruses As a Molecular Tool to Monitor Humoral Immune Responses Against SARS-CoV-2 Via Neutralization Assay

Published on: November 21, 2023

相关概念视频

Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...